About Shanghai Cell Therapy Group
Shanghai Cell Therapy Group is a company based in Shanghai (China) founded in 2014.. Shanghai Cell Therapy Group has raised $201.91 million across 4 funding rounds from investors including China Pacific Insurance, China Asset Management and Jiuzhou Venture Capital. Shanghai Cell Therapy Group operates in a competitive market with competitors including Blue Rock Therapeutics, CellCarta, Ascend, Impel Pharmaceuticals and RiboPro, among others.
- Headquarter Shanghai, China
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$201.91 M (USD)
in 4 rounds
-
Latest Funding Round
-
Investors
China Pacific Insurance
& 6 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Shanghai Cell Therapy Group
Shanghai Cell Therapy Group has successfully raised a total of $201.91M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Last Round
-
First Round
First Round
(01 Jun 2016)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2021 | Amount | Series D - Shanghai Cell Therapy Group | Valuation | Jiuzhou Venture Capital , CCB International |
|
| Dec, 2018 | Amount | Series C - Shanghai Cell Therapy Group | Valuation |
investors |
|
| Nov, 2018 | Amount | Series C - Shanghai Cell Therapy Group | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Shanghai Cell Therapy Group
Shanghai Cell Therapy Group has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include China Pacific Insurance, China Asset Management and Jiuzhou Venture Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Shanghai Cell Therapy Group
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Shanghai Cell Therapy Group
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Shanghai Cell Therapy Group Comparisons
Competitors of Shanghai Cell Therapy Group
Shanghai Cell Therapy Group operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Blue Rock Therapeutics, CellCarta, Ascend, Impel Pharmaceuticals and RiboPro, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Stem cell therapies are developed for cardiovascular and neurological diseases.
|
|
| domain | founded_year | HQ Location |
Histopathology and genomics services are offered by the CRO.
|
|
| domain | founded_year | HQ Location |
Online insurance payments and premium financing are enabled for businesses.
|
|
| domain | founded_year | HQ Location |
Transformative therapies are developed and commercialized through specialized services.
|
|
| domain | founded_year | HQ Location |
Online supplier and developer of RNA based products
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Shanghai Cell Therapy Group
Frequently Asked Questions about Shanghai Cell Therapy Group
When was Shanghai Cell Therapy Group founded?
Shanghai Cell Therapy Group was founded in 2014 and raised its 1st funding round 2 years after it was founded.
Where is Shanghai Cell Therapy Group located?
Shanghai Cell Therapy Group is headquartered in Shanghai, China.
Is Shanghai Cell Therapy Group a funded company?
Shanghai Cell Therapy Group is a funded company, having raised a total of $201.91M across 4 funding rounds to date. The company's 1st funding round was a Series C of $39.6M, raised on Jun 01, 2016.
What does Shanghai Cell Therapy Group do?
Shanghai Cell Therapy Group was founded in 2014 and is based in Shanghai, China. Operations are focused on the biotechnology sector, with services centered on research and development for cell therapies. Expertise is applied to various stages of cell-based treatment development, including preclinical studies and innovation support. The company serves clients in the medical and pharmaceutical fields through tailored RD solutions in this specialized domain.
Who are the top competitors of Shanghai Cell Therapy Group?
Shanghai Cell Therapy Group's top competitors include Blue Rock Therapeutics, Ascend and CellCarta.
Who are Shanghai Cell Therapy Group's investors?
Shanghai Cell Therapy Group has 7 investors. Key investors include China Pacific Insurance, China Asset Management, Jiuzhou Venture Capital, CCB International, and Haier Capital.